Related Experiment Video
Updated: Feb 16, 2026

Platelet-Rich Plasma Lysate for Treatment of Eye Surface Diseases
Published on: August 2, 2022
EANM procedure guideline for 32P phosphate treatment of myeloproliferative diseases
Jan Tennvall1, Boudewijn Brans
1Department of Oncology, Lund University Hospital, 221 85 Lund, Sweden. Jan.Tennvall@med.lu.se
Introduction:
(32)P phosphate was the first therapeutic radioisotope, used in leukaemia about 70 years ago. Since then, many new agents for haematological proliferations have been introduced successfully. Today there remains a distinct subgroup of elderly patients with polycythaemia vera and essential thrombocythaemia for whom (32)P is the most optimal treatment option, an assertion supported by two large studies with long follow-up.
Purpose:
The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for (32)P phosphate therapy.
Related Concept Videos
Guidelines for Sketching a Curve
Pre-Procedural Guidelines for Assessing Blood Pressure
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Alzheimer's Disease: Treatment
Phosphate Buffer
Sodium dihydrogen phosphate does not fully dissociate in neutral or acidic solutions. When a strong base, such as sodium hydroxide (NaOH), is introduced into the solution, sodium dihydrogen phosphate...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

